NCT06137300View on ClinicalTrials.gov

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

NANot yet recruitingINTERVENTIONAL
Enrollment

986

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Urinary kallidinogenase for injection

Urinary kallidinogenase 0.15PNA once daily for 7 days.

OTHER

Guideline-prescribed medical therapy

Guideline-prescribed medical therapy

Trial Locations (1)

130000

First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yi Yang

OTHER

NCT06137300 - Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter